BL-B01D1

• Target:

  Antibody-Drug Conjugates (ADCs) |||EGFR

• Related Pathways:

  Angiogenesis|||JAK/STAT signaling|||Antibody-drug Conjugate/ADC Related|||Tyrosine Kinase/Adaptors

• Bioactivity:

  BL-B01D1 is a bispecific ADC that targets EGFR and HER3 via the bispecific antibody Izalontamab. It exerts cytotoxic effects on various cancer cells by using its ADC toxin ED04 to inhibit DNA replication and synthesis.

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C